Table 2.
Patient Characteristics (N = 63)
| Characteristic | N (%) |
|---|---|
| Gender | |
| Male | 49 (78) |
| Female | 14 (22) |
| Age (y) | |
| Median | 60 |
| Range | 35–80 |
| Histology | |
| Clear cell | 63 (100) |
| Prior nephrectomy | |
| Yes | 56 (89) |
| No. of systemic therapies | |
| 0 | 23 (37) |
| 1 | 24 (38) |
| ≥2 | 16 (25) |
| Prior therapy | |
| Cytokines | 30 (48) |
| TKIs | 15 (24) |
| ECOG PSa | |
| 0 | 42 (67) |
| 1 | 12 (19) |
| 2 | 1 (2) |
| CCF TKI risk group | |
| Favorable | 23 (37) |
| Intermediate | 18 (29) |
| Unfavorable | 13 (21) |
| Unknown | 9 (14) |
| Tumor reduction (%) | |
| Median | 30.0 |
| Range | −35–100 |
| PFS (mo) | |
| Median | 20.4 |
| Baseline SBP (mmHg) | |
| Median | 139 |
| Range | 93–190 |
| Baseline SBP >150 mmHg | 18 (29) |
| Baseline DBP (mmHg) | |
| Median | 80 |
| Range | 47–103 |
| Baseline DBP >90 mmHg | 13 (21) |
| Baseline SBP >150 and/or DBP >90 mmHg | 24 (38) |
| On Anti-HTN med(s) at baseline | |
| Yes | 36 (57) |
Abbreviations: CCF TKI, Cleveland Clinic Foundation tyrosine kinase inhibitor; DBP, diastolic blood pressure; ECOG PS, Eastern Cooperative Oncology Group performance status; HTN, hypertension; Med(s), medications; PFS, progression free survival; SBP, systolic blood pressure.